Lipid construct for delivery of insulin to a mammal

Abstract

The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

1 - 75 . (canceled) 
     
     
         76 . A composition comprising a three-dimensional (3D) lipid-based particle enclosed by a bipolar lipid membrane,
 wherein the bipolar lipid membrane comprises cholesterol, dicetyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphocholine, and a hepatocyte receptor binding molecule,
 wherein the hepatocyte receptor binding molecule comprises at least one biotin-containing compound selected from the group consisting of biotin DHPE (2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate); and biotin-X-DHPE (2,3-diacetoxypropyl 2-(6-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamido) ethyl phosphate); 
   wherein the at least one biotin-containing compound extends outward from the 3D lipid-based particle and binds to a hepatocyte receptor;   wherein the composition further comprises an insulin which is dispersed within the 3D lipid-based particle and is not covalently bound to the 3D lipid-based particle; and,   wherein the size of the 3D lipid-based particle ranges from 0.0200 to 0.40 μm.   
     
     
         77 . The composition of  claim 76 , wherein the 3D-lipid particle is suspended in an aqueous solution, which comprises a free dissolved insulin that is not dispersed within the 3D lipid-based particle. 
     
     
         78 . The composition of  claim 76 , wherein the insulin dispersed within the 3D lipid-based particle is selected from the group consisting of insulin lispro, insulin aspart, regular insulin, insulin glargine, insulin zinc, extended human insulin zinc suspension, isophane insulin, human buffered regular insulin, insulin glulisine, recombinant human regular insulin, and recombinant human insulin isophane. 
     
     
         79 . The composition of  claim 77 , wherein the free dissolved insulin are independently selected from the group consisting of insulin lispro, insulin aspart, regular-insulin, insulin glargine, insulin zinc, extended human insulin zinc suspension, isophane insulin, human buffered regular insulin, insulin glulisine, recombinant human regular insulin, and recombinant human insulin isophane. 
     
     
         80 . The composition of  claim 76 , wherein the membrane further comprises at least one lipid selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl). 
     
     
         81 . The composition of  claim 76 , further comprising cellulose acetate phthalate. 
     
     
         82 . The composition of  claim 76 , further comprising at least one charged organic molecule bound to the insulin dispersed within the 3D lipid-based particle, wherein the charged organic molecule is at least one selected from the group consisting of protamines, polylysine, poly (arg-pro-thr) n  in a mole ratio of 1:1:1, poly (DL-Ala-poly-L-lys) n  in a mole ratio of 6:1, histones, sugar polymers comprising a primary amino group, polynucleotides with primary amino groups, proteins comprising amino acid residues with carboxyl (COO − ) or sulfhydral (S − ) functional groups, acidic polymers, and sugar polymers containing carboxyl groups.